Pipeline

NK105 Paclitaxel Micelle / Indication : Stomach Cancer

Phase III Clinical Trial
Phase I Clinical Trial
Paclitaxel (generic name) is an anticancer drug mostly used in the treatment of ovarian, non-small cell lung, breast and stomach cancers etc.This chemotherapy forms the drug category of the taxanes. Paclitaxel works by interfering with normal microtubule growth during cell division, thus blocking the growth of the cancer.

A number of side effects are associated with alcohol-based solvents which are used to solubilize paclitaxel. Moreover, additional medicines, such as steroids, antihistamines and antiulcerogenic drug, are used to reduce side effects.

NanoCarrier has prepared micellar nanoparticles encapsulating paclitaxel utilizing micellar nanoparticle technology, with the aim to reduce the above mentioned side effects. Based on this, we entered into a joint research with Nippon Kayaku Co., Ltd and developed new formulation of micellar nanoparticles, which reduce above mentioned disadvantages. We entered into a license agreement with Nippon Kayaku Co., Ltd. for this new paclitaxel micelles. NK105 is currently in clinical trials by Nippon Kayaku.
Regarding NK105, Nippon Kayaku Co., Ltd., to which we granted the license,is planning an additional clinical trial of PIII for breast cancer,according to the presentation material of financial results for the third quarter of the fiscal year ending March 31, 2017, which was released on January 31,2017.